Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology

Introduction: Bevacizumab (Avastin; Genetech Inc., South San Francisco, CA) and ranibizumab (Lucentis, Genetech Inc.) are two anti-Vascular Endothelial Growth Factor (VEGF) agents used in increasing amounts off-label to treat ocular conditions. To date, no study has quantified how far reaching these...

Descripción completa

Detalles Bibliográficos
Autores principales: Micieli, Jonathan A., Micieli, Micieli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: McGill University 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399721/
https://www.ncbi.nlm.nih.gov/pubmed/22815647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399721/
https://www.ncbi.nlm.nih.gov/pubmed/22815647

Ejemplares similares